Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

A First-in-human, Dose Escalation, and Expansion Study of BNT3211 for Participants With Advanced Solid Tumors

16. listopadu 2026 aktualizováno: BioNTech SE

A Phase I/II, First-in-human, Open-label, Multi-site, Dose Escalation and Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNT3211 in Participants With Advanced Solid Tumors

This study is the first time BNT3211 will be tested in people. It will evaluate different dose levels of BNT3211 in adults to find suitable doses and to understand how safe the treatment is and how it may help people with advanced solid tumors.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

This study will consist of two parts (A and B). Part A will be a dose escalation to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BNT3211. Part B will be a dose optimization and proof-of-concept to further investigate the safety, tolerability and preliminarily antitumor activity of BNT3211 at doses selected from Part A. Part B will enroll participants with the same indications as in Part A.

No randomization will be performed in Part A. In Part B, for each selected indication, participants are randomized to the doses selected at the end of Part A using a dynamic allocation procedure.

There will be a screening period, a treatment period, and a follow-up period (including an end-of-treatment visit, a safety follow-up visit, and a survival follow-up period with regular visits).

Participants will receive BNT3211 until disease progression, start of new anticancer treatment, unacceptable toxicity, withdrawal of consent, or until the sponsor terminates the study or any other criterion for discontinuation is met.

Typ studie

Intervenční

Zápis (Odhadovaný)

345

Fáze

  • Fáze 2
  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: BioNTech clinical trials patient information
  • Telefonní číslo: +49 6131 9084
  • E-mail: patients@biontech.de

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Key Inclusion Criteria:

  • Are ≥18 years of age (local laws will be followed if the age of consent is older).
  • Have an Eastern Cooperative Oncology Group performance status of 0 to 1.
  • Have a life expectancy of ≥3 months in the opinion of the investigator.
  • Have at least one measurable lesion as per RECIST v1.1.
  • Have an archival formalin-fixed paraffin-embedded tumor tissue sample available or are willing to be biopsied to obtain a fresh tumor tissue sample.
  • Have histologically or cytologically confirmed locally advanced, recurrent, or metastatic solid tumors and must have received all available standard of care (SoC) treatment in accordance with local practice (unless the standard therapy is considered inappropriate or intolerable) and failed at least first-line SoC therapy prior to enrollment.
  • Have an adequate coagulation, hematologic, and organ function as defined by the protocol.
  • Left ventricular ejection fraction (LVEF) ≥50% by either echocardiogram or multi-gated acquisition scan within 28 days prior to first dose of study treatment.

Key Exclusion Criteria:

  • Have had major surgery (not including diagnostic surgery) within the 4 weeks prior to the first dose of study treatment or are planned to undergo major surgery during the course of the study.

  • Have had prior allogeneic bone marrow transplantation or solid-organ transplantation.

  • Have had an inadequate washout period for prior anticancer treatment or other restricted medications prior to the first dose of investigational medicinal product (IMP) as defined in the protocol.

  • Have received systemic steroids (>10 mg/day of prednisone or its equivalent) or other immunosuppressive therapy within 2 weeks prior to the first dose of IMP. Protocol defined exceptions apply.

  • Have received any live or attenuated vaccine within 4 weeks prior to the first dose of IMP or intend to receive a live or attenuated vaccine during the study.

  • Have a history of leptomeningeal carcinomatosis.

  • Have brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anticonvulsants for at least 2 weeks prior to the first dose of IMP.

  • Have a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that requires steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. Protocol-defined exceptions apply.

  • Have clinically significant concomitant pulmonary disease, including but not limited to: chronic obstructive pulmonary disease, restrictive lung disease, lung injury accompanied with autoimmune disease/connective tissue disorders.

  • Have uncontrolled pleural effusions, ascites, or pericardial effusions that require repeated drainage (once monthly or more frequently).

  • Have active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal conditions that may cause bleeding or perforation in the opinion of the treating investigator.

  • Have an active infection that requires systemic therapy (except for oral antibiotics) within 1 week prior to the first dose of IMP. Participants receiving prophylactic anti-infective therapy (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) may be eligible.

  • Have active or chronic corneal disorders, or other active ocular conditions requiring ongoing therapy, or any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy.

  • Have a known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Protocol defined exceptions apply.

  • Have any other primary malignancy within 3 years prior to the first dose of IMP, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other curatively treated solid tumors.

  • Have unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved according to (US) National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Grade ≤1 (unless the investigator determines that certain AEs pose no safety risk to the participant, such as hair loss, Grade 2 peripheral neuropathy or stable hypothyroidism under hormone replacement therapy).

  • Have any of the following heart conditions within 6 months prior to the study treatment:

    • Acute coronary syndrome, coronary artery bypass grafting, congestive heart failure, aortic dissection, stroke, or other Grade 3 and above cardiovascular and cerebrovascular events.
    • New York Heart Association functional classification ≥II heart failure or LVEF <50%.
    • Ventricular arrhythmias requiring clinical intervention, second- to third-degree atrioventricular block, or congenital long QT syndrome. Participants with treated cardiac arrhythmia/atrial fibrillation are allowed.
    • Mean QT interval corrected by Fridericia's method >450 ms for males or >470 ms for females in three successive screening measurements based on a 12-lead electrocardiogram.
  • Unstable thrombotic event (e.g., deep vein thrombosis, arterial thrombosis, pulmonary embolism) requiring therapeutic intervention within 3 months.

Note: Other protocol defined inclusion and exclusion criteria apply.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Nerandomizované
  • Intervenční model: Sekvenční přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Part A (dose escalation) - BNT3211 monotherapy

Escalating dose levels of BNT3211.

Intravenous infusion

Experimentální: Part B (dose optimization) - BNT3211 monotherapy

Indications as in Part A. Doses will be selected from Part A.

Intravenous infusion

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Part A only - Occurrence of dose-limiting toxicities (DLTs) during the DLT evaluation period
Časové okno: Up to 21 days from the initiation of first dose of BNT3211

DLT period defined as the first 21 days. Per dose level.

Up to 21 days from the initiation of first dose of BNT3211
Number of participants with treatment emergent adverse events (TEAEs), Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related TEAEs, treatment-related Grade ≥3 TEAEs, and treatment-related SAEs
Časové okno: From first dose until 35 days after the last dose of BNT3211 (up to 36 months)

Per dose level (Part A) and per arm (Part B).

From first dose until 35 days after the last dose of BNT3211 (up to 36 months)
Number of participants with dose interruptions, reductions, or discontinuations of study treatment due to TEAEs
Časové okno: From the first until the last dose of BNT3211 (up to 36 months)

Per dose level (Part A) and per arm (Part B).

From the first until the last dose of BNT3211 (up to 36 months)
Part B only - Objective response rate
Časové okno: Up to 36 months

Defined as the proportion of participants with confirmed complete response (CR) or partial response (PR) (per the Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1] based on the investigator's assessment) is observed as best overall response. Per arm.

Up to 36 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
PK assessment: Area under the curve (AUC) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
Časové okno: Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)

After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits.

Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
PK assessment: Maximum concentration (Cmax) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
Časové okno: Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)

After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits.

Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
PK assessment: Time to reach maximum (peak) serum concentration (Tmax) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
Časové okno: Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)

After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits.

Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
PK assessment: Elimination half-life (t1/2) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
Časové okno: Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)

After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits.

Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
Part A only - Objective response rate
Časové okno: Up to 36 months

Defined as the proportion of participants with confirmed CR or PR (per RECIST v1.1 based on the investigator's assessment) is observed as best overall response. Per dose level.

Up to 36 months
Disease control rate
Časové okno: Up to 36 months

Defined as the proportion of participants in whom a confirmed CR, confirmed PR or stable disease (SD) (per RECIST v1.1 based on the investigator's assessment, SD assessed at least 6 weeks [±7 days] after the first BNT3211 dose) is observed as best overall response. Per dose level (Part A) and per arm (Part B).

Up to 36 months
Duration of response
Časové okno: Up to 36 months

Defined as the time from first objective response (CR or PR per RECIST v1.1 based on the investigator's assessment) to first occurrence of objective tumor progression (progressive disease per RECIST v1.1 based on the investigator's assessment) or death from any cause, whichever occurs first. Per dose level (Part A) and per arm (Part B).

Up to 36 months
Part B only - Progression free survival
Časové okno: Up to 36 months

Defined as the time from first dose of BNT3211 to first objective tumor progression (PD per RECIST 1.1 based on the investigator's assessment), or death from any cause, whichever occurs first. Per arm.

Up to 36 months
Part B only - Overall survival
Časové okno: Up to 36 months

Defined as the time from first dose of BNT3211 to death from any cause. Per arm.

Up to 36 months
Anti-drug antibody prevalence
Časové okno: For up to 35 days from the last dose of BNT3211 (up to 36 months)

Defined as proportion of participants who are anti-drug antibody positive (either baseline or post-baseline). Per dose level (Part A) and per arm (Part B). As data permits.

For up to 35 days from the last dose of BNT3211 (up to 36 months)
Anti-drug antibody incidence
Časové okno: For up to approximately 35 days from the last dose of BNT3211 (up to 36 months)

Defined as proportion of participants having treatment-emergent anti-drug antibodies. Per dose level (Part A) and per arm (Part B). As data permits.

For up to approximately 35 days from the last dose of BNT3211 (up to 36 months)

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Spolupracovníci

Vyšetřovatelé

  • Ředitel studie: BioNTech Responsible Person, BioNTech SE

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. listopadu 2026

Primární dokončení (Odhadovaný)

1. října 2029

Dokončení studie (Odhadovaný)

1. března 2030

Termíny zápisu do studia

První předloženo

16. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

16. listopadu 2026

První zveřejněno (Aktuální)

20. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

20. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

16. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • BNT3211-01

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .